PPH - ETF AI Analysis
Top Page
VanEck Pharmaceutical ETF (PPH)
Rating:73Outperform
Price Target:―
Positive Factors
Large, Established Pharma Holdings
The ETF is built around well-known global pharmaceutical companies, which tend to have stable businesses and strong competitive positions.
Several Strong-Performing Top Stocks
Many of the largest holdings have shown solid gains so far this year, helping support the fund’s overall results.
Meaningful Asset Base
The fund manages a sizable pool of assets, which can help with trading liquidity and reduce the impact of large investor moves.
Negative Factors
High Stock Concentration
A small number of companies make up a large share of the portfolio, so weakness in just one or two names can significantly affect returns.
Single-Sector Focus
Almost all assets are in the health care sector, leaving investors heavily exposed to industry-specific risks like drug pricing and regulation.
Mixed Recent Performance
The fund’s short-term results have been choppy, with some key holdings showing weak performance that has weighed on returns.
PPH vs. SPDR S&P 500 ETF (SPY)
AUM943.40M
RegionGlobal
Expense Ratio0.36%
Beta0.45
IssuerVanEck
Inception DateDec 20, 2011
Dividend Yield2.16%
Asset ClassEquity
Index TrackedMVIS US Listed Pharmaceutical 25
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume126,428
30 Day Avg. Volume364,736
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
124.45Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering25
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PPH Summary
The VanEck Pharmaceutical ETF (PPH) is a fund that follows the MVIS US Listed Pharmaceutical 25 Index, focusing on large drug and medicine makers. It holds big, well-known companies like Eli Lilly and Pfizer, which develop and sell treatments for many health conditions. Someone might invest in PPH to get broad exposure to the pharmaceutical industry in a single investment, aiming for long-term growth as populations age and healthcare spending rises. A key risk is that it is heavily concentrated in pharmaceutical and health care stocks, so its value can rise or fall sharply with news about drug approvals, regulations, or healthcare policy.
How much will it cost me?The VanEck Pharmaceutical ETF (PPH) has an expense ratio of 0.36%, which means you’ll pay $3.60 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it focuses on a specialized sector, the pharmaceutical industry, which may require more research and management to track effectively.
What would affect this ETF?The VanEck Pharmaceutical ETF (PPH) could benefit from trends like aging populations, increased healthcare spending, and advancements in medical research, which drive demand for innovative treatments and medications. However, it may face challenges from regulatory changes, patent expirations, or pricing pressures in the pharmaceutical industry, which could impact the profitability of its top holdings like Eli Lilly, Novartis, and Pfizer.
PPH Top 10 Holdings
PPH is a pure play on Big Pharma, with Eli Lilly sitting in the driver’s seat but recently losing steam after a strong run, which has taken some shine off the fund. Offsetting that, steadier names like Novartis, Merck, and Pfizer have been quietly rising, helping to keep performance on a more even keel. Novo Nordisk has been a bit of a roller coaster, rebounding lately but still looking mixed overall. With nearly all its weight in large global drugmakers across the U.S. and Europe, this ETF is highly concentrated in the pharmaceutical giants shaping worldwide healthcare.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 18.58% | $179.49M | $835.18B | -1.03% | 72 Outperform | |
| Novartis | 10.65% | $102.89M | $263.90B | 28.02% | 80 Outperform | |
| Merck & Company | 9.36% | $90.40M | $276.38B | 32.50% | 80 Outperform | |
| Novo Nordisk | 5.57% | $53.81M | $181.09B | -34.21% | 73 Outperform | |
| Pfizer | 5.20% | $50.20M | $153.59B | 16.22% | 74 Outperform | |
| Sanofi | 4.75% | $45.85M | $112.92B | -13.00% | 75 Outperform | |
| GlaxoSmithKline | 4.69% | $45.32M | $109.05B | 42.46% | 77 Outperform | |
| Bristol-Myers Squibb | 4.65% | $44.95M | $119.87B | 19.23% | 78 Outperform | |
| AstraZeneca | 4.38% | $42.27M | $292.69B | 32.74% | 80 Outperform | |
| McKesson | 4.21% | $40.70M | $101.43B | 18.38% | 62 Neutral |
PPH Technical Analysis
Negative
―
Price Trends
104.41
Negative
104.09
Negative
96.90
Positive
Market Momentum
-0.98
Positive
37.12
Neutral
6.40
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PPH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 102.82, equal to the 50-day MA of 104.41, and equal to the 200-day MA of 96.90, indicating a neutral trend. The MACD of -0.98 indicates Positive momentum. The RSI at 37.12 is Neutral, neither overbought nor oversold. The STOCH value of 6.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPH.
PPH Peer Comparison
Comparison Results
Performance Comparison
PPH
VanEck Pharmaceutical ETF
98.87
11.39
13.02%
SLVP
iShares MSCI Global Silver Miners ETF
―
―
―
GII
SPDR S&P Global Infrastructure ETF
―
―
―
BKGI
BNY Mellon Global Infrastructure Income ETF
―
―
―
BBH
VanEck Biotech ETF
―
―
―
CANC
Tema Oncology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents